Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Development Officer Conference Call Participants Jonathan Miller - Evercore Matt Phipps - William Blair Operator Good day, ladies and gentlemen. And welcome to the Pieris Pharmaceuticals to host First Quarter 2023 Investor Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your h ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada EIN 30-0784346 (S ...

12 31 moderate asthmatics controlled on standard-of-care therapy (medium dose ICS with LABA) were dosed twice daily over four weeks randomized across two dose levels and placebo (1:1:1) Safety review performed of the following (compared to placebo): Changes in laboratory markers (immune biomarkers, clinical chemistry, and hematology) Pharmacokinetics Potential Large Market Opportunity in Moderate-to-Severe Asthma not Addressed by ICS/LABA before Injectable Biologics 3 5 INTERMITTENT AND MILD MILD-TO-MODERAT ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer Mary Fitzgerald - Vice President, Project Leader Elarekibep Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Rob Andrew - William Blair & Company Operator Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Confe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State o ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Thomas Bures - SVP & CFO Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Chief Development Officer Conference Call Participants Jonathan Miller - Evercore ISI Matthew Phipps - William Blair & Company Jiale Song - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions]. At thi ...

PIERIS PHARMACEUTICALS CORPORATE PRESENTATION November 2022 SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, whether PRS-220 will ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder - President and Chief Executive Officer Hitto Kaufmann - Chief Scientific Officer Shane Olwill - Chief Development Officer Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Matt Phipps - William Blair Operator Good morning, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals Second Quarter Earnin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State or other juri ...

PIERIS PHARMACEUTICALS CORPORATE PRESENTATION May 2022 SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing for initiation ...